Toleranzia AB (TOL) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.023x

Based on the latest financial reports, Toleranzia AB (TOL) has a cash flow conversion efficiency ratio of -0.023x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.98 Million ≈ $-428.10K USD) by net assets (Skr173.87 Million ≈ $18.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Toleranzia AB - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Toleranzia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Toleranzia AB (TOL) total liabilities for a breakdown of total debt and financial obligations.

Toleranzia AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Toleranzia AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Pivotal Metals Ltd
AU:PVT
-0.012x
Nur Ink Innovations Ltd
TA:NURI
-0.351x
Vishwaraj Sugar Industries Limited
NSE:VISHWARAJ
-0.120x
MENNICA SKARB.AB ZY -10
F:98S
N/A
Clean & Science co. Ltd
KQ:045520
0.147x
Evion Group NL
AU:EVG
-0.122x
Narmada Agrobase Limited
NSE:NARMADA
0.002x
SSH Group Ltd
AU:SSH
0.196x

Annual Cash Flow Conversion Efficiency for Toleranzia AB (2014–2024)

The table below shows the annual cash flow conversion efficiency of Toleranzia AB from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Toleranzia AB.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr180.07 Million
≈ $19.38 Million
Skr-10.28 Million
≈ $-1.11 Million
-0.057x -38.60%
2023-12-31 Skr153.52 Million
≈ $16.52 Million
Skr-6.32 Million
≈ $-680.46K
-0.041x +31.64%
2022-12-31 Skr119.51 Million
≈ $12.86 Million
Skr-7.20 Million
≈ $-774.83K
-0.060x -12.56%
2021-12-31 Skr127.97 Million
≈ $13.77 Million
Skr-6.85 Million
≈ $-737.10K
-0.054x +8.91%
2020-12-31 Skr67.92 Million
≈ $7.31 Million
Skr-3.99 Million
≈ $-429.53K
-0.059x +53.62%
2019-12-31 Skr34.99 Million
≈ $3.77 Million
Skr-4.43 Million
≈ $-477.06K
-0.127x +27.53%
2018-12-31 Skr27.59 Million
≈ $2.97 Million
Skr-4.82 Million
≈ $-519.03K
-0.175x +54.26%
2017-12-31 Skr14.67 Million
≈ $1.58 Million
Skr-5.61 Million
≈ $-603.27K
-0.382x -46.00%
2016-12-31 Skr20.06 Million
≈ $2.16 Million
Skr-5.25 Million
≈ $-565.11K
-0.262x -90.44%
2015-12-31 Skr24.45 Million
≈ $2.63 Million
Skr-3.36 Million
≈ $-361.73K
-0.137x +74.75%
2014-12-31 Skr1.72 Million
≈ $184.88K
Skr-935.22K
≈ $-100.65K
-0.544x --

About Toleranzia AB

ST:TOL Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$13.91 Million
Skr129.25 Million SEK
Market Cap Rank
#26045 Global
#553 in Sweden
Share Price
Skr0.48
Change (1 day)
+0.00%
52-Week Range
Skr0.43 - Skr0.50
All Time High
Skr1.88
About

Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more